Journal of Pharmacy Practice · 1999 · 38 citations · 23 references
Life SciencesImmunologyPharmacotherapyAutoimmunityInflammationRheumatologyAutoantibodiesAutoimmune DiseasesAutoimmune Rheumatic DiseasesRenal DiseaseSystemic Autoimmune DiseaseSystemic Lupus ErythematosusCardiopulmonary ComplicationsCardiopulmonary InvolvementCardiovascular InvolvementInflammatory Tissue DamageSystemic Lupus Erythematosus AssociationsTissue Damage MechanismsTopical Nonsteroidal Anti-inflammatory DrugsTreatment With Topical Corticosteroids
Systemic lupus erythematosus (SLE) is a chronic, multiple-organ system inflammatory disorder associated with immune system dysfunction. Autoantibodies are produced that react with self-antigens in cell membranes and nuclear and cytoplasmic constituents to produce tissue damage. Commonly observed clinical manifestations include arthritis, myalgia, fever, cutaneous lesions, cytopenia, and renal, CNS, and cardiopulmonary involvement. Minor manifestations can be managed with relatively nontoxic agents such as nonsteroidal anti-inflammatory drugs, topical corticosteroids, and antimalarials. Severe disease involving the kidneys, CNS, and cardiopulmonary systems requires the aggressive use of more toxic agents such as high-dose corticosteroids, azathioprine, and cyclophosphamide. Other supportive and ancillary therapies are also required to manage the complications frequently associated with SLE.
23
The 1982 revised criteria for the classification of systemic lupus erythematosus
Eng M. Tan, Alan S. Cohen, James F. Fries et al. · Arthritis & Rheumatism · 1982 · 14.6K citations
Howard A. Austin, John H. Klippel, James E. Balow et al. · New England Journal of Medicine · 1986 · 1.2K citations
Outcome in Systemic Lupus Erythematosus
Helgi Jónsson, Ola Nived, Gunnar Sturfelt · Medicine · 1989 · 316 citations
A study of fatigue in systemic lupus erythematosus.
Lauren Krupp, Nicholas G. LaRocca, Joanne Muir et al. · PubMed · 1990 · 204 citations